MA54985A - Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 - Google Patents
Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1Info
- Publication number
- MA54985A MA54985A MA054985A MA54985A MA54985A MA 54985 A MA54985 A MA 54985A MA 054985 A MA054985 A MA 054985A MA 54985 A MA54985 A MA 54985A MA 54985 A MA54985 A MA 54985A
- Authority
- MA
- Morocco
- Prior art keywords
- bioisostery
- pharmacophores
- mcl
- antagonists
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862638846P | 2018-03-05 | 2018-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54985A true MA54985A (fr) | 2021-12-29 |
Family
ID=65991891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054985A MA54985A (fr) | 2018-03-05 | 2019-03-04 | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11274105B2 (fr) |
| EP (1) | EP3762393B1 (fr) |
| MA (1) | MA54985A (fr) |
| WO (1) | WO2019173181A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3668878A1 (fr) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Composés inhibant la protéine mcl-1 |
| WO2019046150A1 (fr) | 2017-08-29 | 2019-03-07 | Amgen Inc. | Composés macrocycliques permettant d'inhiber la protéine mcl-1 |
| EP3793565B1 (fr) | 2018-05-14 | 2022-01-05 | Gilead Sciences, Inc. | Inhibiteurs mcl-1 |
| WO2021047616A1 (fr) * | 2019-09-12 | 2021-03-18 | 苏州亚盛药业有限公司 | Composé spiro à base d'heptane hétérocyclique d'oxynitrure, intermédiaire et procédé de préparation associé |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| AU2020391106B2 (en) | 2019-11-26 | 2024-03-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| BR112022022408A2 (pt) * | 2020-05-06 | 2022-12-13 | Amgen Inc | Síntese de intermediários de álcool vinílico |
| JP2023528965A (ja) | 2020-06-10 | 2023-07-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としての大環状２－アミノ－３－フルオロ－ブタ－３－エナミド |
| CN116457334A (zh) * | 2020-11-19 | 2023-07-18 | 吉利德科学公司 | 用于制备大环mcl1抑制剂的方法和中间体 |
| KR20230121806A (ko) | 2020-12-17 | 2023-08-21 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 마크로사이클릭 분지형 3-플루오로-부트-3-엔아미드 |
| JP2024516641A (ja) | 2021-04-26 | 2024-04-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状２－アリルテトラヒドロフラン |
| WO2022261301A1 (fr) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Inhibiteurs de mcl-1 en combinaison avec des agents anticancéreux |
| KR20240019330A (ko) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 저해제와 항체 약물 접합체의 조합 |
| KR20240107105A (ko) | 2021-11-16 | 2024-07-08 | 얀센 파마슈티카 엔브이 | Mcl-1의 억제제로서의 매크로사이클릭 2-아미노-부트-3-엔아미드 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| ES2705599T3 (es) | 2007-04-16 | 2019-03-26 | Abbvie Inc | Indoles sustituidos en la posición 7 como inhibidores de mcl-1 |
| WO2011094708A2 (fr) | 2010-01-29 | 2011-08-04 | Dana-Farber Cancer Institute, Inc | Petites molécules pour la modulation de mcl-1 et procédés de modulation de la mort cellulaire, la division cellulaire, la différenciation cellulaire et procédés de traitement de troubles |
| US9486422B2 (en) | 2011-10-06 | 2016-11-08 | The Regents Of The University Of Michigan | Small molecule inhibitors of Mcl-1 and the uses of thereof |
| US9914723B2 (en) | 2012-03-29 | 2018-03-13 | The Regents Of The University Of Michigan | Small molecule inhibitors of Mcl-1 and uses thereof |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| WO2017147410A1 (fr) | 2016-02-25 | 2017-08-31 | Amgen Inc. | Composés inhibant la protéine mcl-1 |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| EP3668878A1 (fr) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Composés inhibant la protéine mcl-1 |
| WO2019046150A1 (fr) | 2017-08-29 | 2019-03-07 | Amgen Inc. | Composés macrocycliques permettant d'inhiber la protéine mcl-1 |
-
2019
- 2019-03-04 EP EP19714512.1A patent/EP3762393B1/fr active Active
- 2019-03-04 US US16/977,527 patent/US11274105B2/en active Active
- 2019-03-04 WO PCT/US2019/020492 patent/WO2019173181A1/fr unknown
- 2019-03-04 MA MA054985A patent/MA54985A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3762393A1 (fr) | 2021-01-13 |
| US20210047344A1 (en) | 2021-02-18 |
| EP3762393B1 (fr) | 2023-01-11 |
| WO2019173181A1 (fr) | 2019-09-12 |
| US11274105B2 (en) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54985A (fr) | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 | |
| MA49043A (fr) | Formulation stable d'anticorps | |
| MA51620A (fr) | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques | |
| MA53921A (fr) | Inhibiteurs de protéine tyrosine phosphatase | |
| MA49512A (fr) | Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation | |
| MA51066A (fr) | Inhibiteurs d'intégrine | |
| ITUA20161821A1 (it) | Sensori ultrasonici per misurare l'irregolarita' del terreno | |
| MA42032A (fr) | Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac | |
| MA51998A (fr) | Nouveaux polymorphes de sel de calcium en tant qu'agents anti-inflammatoires, immunomodulateurs et anti-prolifératifs | |
| MA54052A (fr) | Formulation d'anticorps | |
| MA53218A (fr) | Antagonistes de l'intégrine | |
| MA54139A (fr) | Formulation d'anticorps | |
| MA45588A (fr) | Formes solides d'un stimulateur de la gcs | |
| MA43685A (fr) | Solutions aqueuses d'acides aminés n-acylés | |
| MA53128A (fr) | Inhibiteurs bicycliques de l'histone désacétylase | |
| FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
| MA55821A (fr) | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression | |
| MA56121A (fr) | Procédés d'identification d'attributs de protéines thérapeutiques | |
| MA53643A (fr) | Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 | |
| MA51902A (fr) | Schémas posologiques d'anticorps b7-h4 | |
| BR112017004134A2 (pt) | ?sondas para imageamento de proteína de huntingtina? | |
| MA55033A (fr) | Formulation d'anticorps thérapeutique | |
| IT201700093172A1 (it) | Metodo per l'identificazione precoce di riacutizzazioni di broncopneumopatia cronica ostruttiva | |
| MA53129A (fr) | Inhibiteurs de l'histone désacétylase | |
| DK3975733T3 (da) | Velsmagende ekstensivt hydrolyserede valleproteinhydrolysater |